Here are the 424B prospectus supplements from QTREX Quantum Ltd. (QTEX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow QTEX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QTEX filings page.
QTREX Quantum Ltd. (symbol QTEX) is conducting a registered direct offering of 11,111,111 Ordinary Shares at $0.90 per share to certain institutional investors, for $10.0 million in gross proceeds. A.G.P./Alliance Global Partners is acting as exclusive placement agent on a reasonable best efforts basis and will receive a $0.063-per-share fee, or $700,000 in total.
QTREX expects net proceeds of about $9.1 million, to be used for working capital and general corporate purposes. Shares outstanding will increase from 55,963,934 to 67,075,045. The company reports a going concern explanatory paragraph in its 2025 financial statements and highlights significant dilution: pro forma as-adjusted net tangible book value would be $0.39 per share versus the $0.90 offering price, implying dilution of $0.51 per share, or 57%, for new investors. QTREX focuses on quantum computing connectivity and an additively manufactured electronics platform while retaining a legacy medical technology subsidiary it is seeking to monetize.